STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
Further to our announcement on 20th October 2015 that Recipharm (STO:RECI) will acquire a majority stake (74%) in Nitin Lifesciences Limited, the Indian Foreign Investment and Promotion Board has now granted approval for this transaction to take place. Closing is expected to take place by the end of Q1 2016.
This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 15 January 2016, at 11:00 am CET.
Further to our announcement on 20th October 2015 that Recipharm (STO:RECI) will acquire a majority stake (74%) in Nitin Lifesciences Limited, the Indian Foreign Investment and Promotion Board has now granted approval for this transaction to take place. Closing is expected to take place by the end of Q1 2016.
This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of NASDAQ Stockholm. This information was submitted for publication on 15 January 2016, at 11:00 am CET.
